Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial)
Conclusion
PREDICT will determine the optimum target Hb for Japanese patients with non-diabetic CKD.
(ClinicalTrials.gov No. NCT01581073).
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Anemia | Aranesp | Chronic Kidney Disease | Diabetes | Dialysis | Endocrinology | Epogen | Kidney Transplant | Kidney Transplantation | Procrit | Statistics | Study | Transplants | Urology & Nephrology